Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)*

Finance & Acquisitions: Phantom Pharmaceuticals

Parents

2021: The company is 68% institutionally owned, with its largest shareholders being Frazier Capital (19% stake), RA Capital Management (15% stake), Invesco (9%), and investor Tadataka Yamada (7%), who's Chairman of the Board and a Venture Partner at Frazier Healthcare.